Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000674535 | SCV000799887 | pathogenic | Lysosomal acid lipase deficiency | 2018-05-09 | criteria provided, single submitter | clinical testing | |
Molecular Diagnostics Laboratory, |
RCV000760967 | SCV000890864 | pathogenic | Wolman disease | 2018-07-17 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000674535 | SCV000893854 | pathogenic | Lysosomal acid lipase deficiency | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000760967 | SCV001582255 | pathogenic | Wolman disease | 2023-12-31 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg65*) in the LIPA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LIPA are known to be pathogenic (PMID: 23485521). This variant is present in population databases (rs779712562, gnomAD 0.005%). This premature translational stop signal has been observed in individual(s) with cholesteryl ester storage disease (PMID: 9554751). This variant is also known as p.Arg44*. ClinVar contains an entry for this variant (Variation ID: 558291). For these reasons, this variant has been classified as Pathogenic. |
Natera, |
RCV000674535 | SCV002091488 | pathogenic | Lysosomal acid lipase deficiency | 2020-12-09 | no assertion criteria provided | clinical testing |